The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals

被引：0
|
作者：
Sigrid Haeggström
Magnus Ingelman-Sundberg
Svante Pääbo
Hugo Zeberg
机构：
[1] Karolinska Institutet,Department of Neuroscience
[2] Karolinska Institutet,Department of Physiology and Pharmacology
[3] Max Planck Institute for Evolutionary Anthropology,Department of Evolutionary Genetics
[4] Okinawa Institute of Science and Technology,Human Evolutionary Genomics Unit
来源：
The Pharmacogenomics Journal | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Genetic variation in genes encoding cytochrome P450 enzymes influences the metabolism of drugs and endogenous compounds. The locus containing the cytochrome genes CYP2C8 and CYP2C9 on chromosome 10 exhibits linkage disequilibrium between the CYP2C8*3 and CYP2C9*2 alleles, forming a haplotype of ~300 kilobases. This haplotype is associated with altered metabolism of several drugs, most notably reduced metabolism of warfarin and phenytoin, leading to toxicity at otherwise therapeutic doses. Here we show that this haplotype is inherited from Neandertals.
引用
收藏
页码：247 / 249
页数：2
相关论文
共 50 条
  • [21] Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population
    Polonikov, Alexey
    Kharchenko, Alexander
    Bykanova, Marina
    Sirotina, Svetlana
    Ponomarenko, Irina
    Bocharova, Anna
    Vagaytseva, Kseniya
    Stepanov, Vadim
    Bushueva, Olga
    Churnosov, Mikhail
    Solodilova, Maria
    GENE, 2017, 627 : 451 - 459
  • [22] Kinetic analysis of fluvastatin metabolism by CYP2C9 and its allelic variants, CYP2C9*2 and CYP2C9*3
    Einolf, HJ
    Fischer, V
    DRUG METABOLISM REVIEWS, 2003, 35 : 191 - 191
  • [23] Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans
    Allabi, AC
    Gala, JL
    Horsmans, Y
    Babaoglu, MO
    Bozkurt, A
    Heusterspreute, M
    Yasar, U
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) : 113 - 118
  • [24] Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5′-hydroxylation
    Iida, I
    Miyata, A
    Arai, M
    Hirota, M
    Akimoto, M
    Higuchi, S
    Kobayashi, K
    Chiba, K
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (01) : 7 - 9
  • [25] Association of polymorphisms in CYP2C8 and CYP2C9 with susceptibility to type 2 diabetes mellitus in a Chinese population
    Wang, Wensu
    Jin, Li
    Shen, Jianguo
    Zhang, Yi
    Zhang, Rong
    GENE REPORTS, 2024, 37
  • [26] Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans
    Guo, YJ
    Zhang, YF
    Wang, Y
    Chen, XY
    Si, DY
    Zhong, DF
    Fawcett, JP
    Zhou, H
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (06) : 749 - 753
  • [27] Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study
    Jorge Vicente
    Fabricio González-Andrade
    Antonia Soriano
    Ana Fanlo
    Begoña Martínez-Jarreta
    Blanca Sinués
    Molecular Biology Reports, 2014, 41 : 1267 - 1272
  • [28] Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study
    Vicente, Jorge
    Gonzalez-Andrade, Fabricio
    Soriano, Antonia
    Fanlo, Ana
    Martinez-Jarreta, Begona
    Sinues, Blanca
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (03) : 1267 - 1272
  • [29] CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype AnalysisA GeT-RM Collaborative Project
    Gaedigk, Andrea
    Boone, Erin C.
    Scherer, Steven E.
    Lee, Seung-been
    Numanagic, Ibrahim
    Sahinalp, Cenk
    Smith, Joshua D.
    McGee, Sean
    Radhakrishnan, Aparna
    Qin, Xiang
    Wang, Wendy Y.
    Farrow, Emily G.
    Gonzaludo, Nina
    Halpern, Aaron L.
    Nickerson, Deborah A.
    Miller, Neil A.
    Pratt, Victoria M.
    Kalman, Lisa, V
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (04): : 337 - 350
  • [30] Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A
    Soyama, A
    Hanioka, N
    Saito, Y
    Murayama, N
    Ando, M
    Ozawa, S
    Sawada, J
    PHARMACOLOGY & TOXICOLOGY, 2002, 91 (04): : 174 - 178
12345